Table 8 Follow-up data of borderline PH, according to definition of PVR cut-off ≥ 3 WU
Group | Group of PH | Background disease | Age at diagnosis | RHC at diagnosis | Desition after first RHC | RHC at final follow up | Desition after final RHC | Outcome | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
mPAP (mmHg) | PVR (WU) | PCWP (mmHg) | mPAP (mmHg) | PVR (WU) | PCWP (mmHg) | |||||||
Boderline PH | 1 | SSc | 37 | 22 | 2.6 | 5 | Follow up | 37 | 2.6 | 9 | Ambrisentan | Deceased because of lung cancer in 14 month |
Boderline PH | 3 | COPD | 65 | 23 | 2.6 | 5 | Follow up | 35 | 3.7 | 4 | Treatment of COPD | Became feasible because of COPD |
Boderline PH | 3 | SSc + Fibrosis | 35 | 20 | 1.2 | 11 | Follow up | 40 | 2.9 | 16 | Treatment of left heart failure | Deceased because of left heart failure in 11 month |
Boderline PH | 4 | CTEPH | 46 | 24 | 2.4 | 7 | Follow up | 19 | 1.1 | 10 | Follow up | Stable |
Boderline pre-capillary PH | 4 | Aortitis | 61 | 24 | 5.8 | 4 | Follow up | 29 | 7.7 | 1 | Riociguat | Improved after the treatment of riociguat |